Louis Boon, PhD

Chief Scientific Officer and Board Member at JJP Biologics

Speaker

JJP Biologics is an innovative new Polish Company and develops the next generation of novel therapeutic biologics around personalized medicine and companion diagnostics (JJP Biologics: Overview | LinkedIn). JJP Biologics lead programs are JJP-1212 an antagonist anti-CD89 antibody and JJP-1008 with application in immune-oncology. Louis was the founder of various biotech companies focused on the generation and development of therapeutic Mabs in the field of cancer and inflammation. Louis is an author of over 390 publications in international scientific journals in the field of medical biotechnology and an inventor on > 20 patent applications.